Prostate Cancer Chemoprevention Study: An investigative randomized control study using purified isoflavones in men with rising prostate-specific antigen

Cancer Science

Volumn 103, Issue 1, 2012, Pages 125-130

  Miyanaga, Naoto ^a,l   Akaza, Hideyuki ^b   Hinotsu, Shiro ^c   Fujioka, Tomoaki ^d   Naito, Seiji ^e   Namiki, Mikio ^f   Takahashi, Satoru ^g   Hirao, Yoshihiko ^h   Horie, Shigeo ⁱ   Tsukamoto, Taiji ^j   Mori, Mitsuru ^j   Tsuji, Hirokazu ^k  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d IWATE MEDICAL UNIVERSITY   (Japan)

^e KYUSHU UNIVERSITY   (Japan)

^f KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^g NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h NARA MEDICAL UNIVERSITY   (Japan)

ⁱ TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

^l Mito Saiseikai General Hospital   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ISOFLAVONE; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PREVENTION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; ILIAC ARTERY OBSTRUCTION; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; AGED; DOUBLE-BLIND METHOD; EQUOL; HUMANS; ISOFLAVONES; JAPAN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84855481687     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02120.x     Document Type: Article

References (19)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Yatani R, Chigusa I, Akazaki K, Stemmermann GN, Welsh RA, Correa P. Geographic pathology of latent prostatic carcinoma. Int J Cancer 1982; 29: 611-6.
3. Coleman MP, Esteve J, Damiecki P, Arslon A, Renard H. Trends in Cancer Incidence and Mortality. IARC Scientific Publication No. 121. Lyon: International Association for Research on Cancer, 1993.
4. Nagata Y, Sonoda T, Mori M et al. Dietary isoflavones may protect against prostate cancer in Japanese men. J Nutr 2007; 137: 1974-9.
5. Kelloff GJ, Crowell JA, Steele VE et al. Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr 2000; 130(2S Suppl): 467S-71S.
6. Venkateswaran V, Klotz LH. Diet and prostate cancer: mechanisms of action and implications for chemoprevention. Nat Rev Urol 2010; 7: 442-53.
7. Lippman SM, Klein EA, Goodman PJ et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301: 39-51.
8. Akaza H, Miyanaga N, Takashima N et al. Is daidzein non-metabolizer a high risk for prostate cancer? A case-controlled study of serum soybean isoflavone concentration. Jpn J Clin Oncol 2002; 32: 296-300.
9. Akaza H, Miyanaga N, Takashima N et al. Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents. Jpn J Clin Oncol 2004; 34: 86-9.
10. Fujimoto K, Tanaka M, Hirao Y et al. Age-stratified serum levels of isoflavones and proportion of equol producers in Japanese and Korean healthy men. Prostate Cancer Prostatic Dis 2008; 11: 252-7.
11. Tsuji H, Moriyama K, Nomoto K, Miyanaga N, Akaza H. Isolation and characterization of the equol-producing bacterium Slackia sp. strain NATTS. Arch Microbiol 2010; 192: 279-87.
12. Kumar NB, Cantor A, Allen K et al. The specific role of isoflavones in reducing prostate cancer risk. Prostate 2004; 59: 141-7.
13. Schröder FH, Roobol MJ, Boevé ER et al. Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement. Eur Urol 2005; 48: 922-30.
14. Mäkelä S, Poutanen M, Kostian ML et al. Inhibition of 17beta-hydroxysteroid oxidoreductase by flavonoids in breast and prostate cancer cells. Proc Soc Exp Biol Med 1998; 217: 310-6.
15. Peterson G, Barnes S. Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation. Prostate 1993; 22: 335-45.
16. Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215-24.
17. Andriole GL, Bostwick DG, Brawley OW et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362: 1192-202.
18. Wilt TJ, Macdonald R, Hagerty K et al. 5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review. BJU Int 2010; 106: 1444-51.
19. Lund TD, Munson DJ, Haldy ME, Setchell KD, Lephart ED, Handa RJ. Equol is a novel anti-androgen that inhibits prostate growth and hormone feedback. Biol Reprod 2004; 70: 1188-95.